Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
01 March 2023 | Story Alicia Pienaar
Prof Mathys Labuschagne
Prof Mathys Labuschagne is the Head of the Clinical Simulation and Skills Unit within the School of Biomedical Sciences in the Faculty of Health Sciences

The Dean of the Faculty of Health Sciences, Prof Gert van Zyl, invites you to the inaugural lecture of Prof Mathys Labuschagne, Head of the Clinical Simulation and Skills Unit within the School of Biomedical Sciences in the Faculty of Health Sciences. 

Subject: Clinical Simulation: Quo Vadis? 
Venue:  Auditorium, Equitas Building, Bloemfontein Campus 
Date: 8 March 2023 
Time: 17:30 

RSVP on or before Friday 3 March 2023

Light refreshments will be served after the inaugural lecture.


About Prof M Labuschagne

Prof Mathys Labuschagne is the Head of the Clinical Simulation and Skills Unit within the School of Biomedical Sciences in the Faculty of Health Sciences at the University of the Free State. He completed his MB ChB degree and qualified as an ophthalmologist in 2006.

He developed an interest in health professions education and obtained a PhD in Health Professions Education in June 2012. The title of his thesis was: Clinical Simulation to enhance undergraduate medical education and training at the University of the Free State.

Prof Labuschagne was appointed Head of the Clinical Simulation and Skills Unit at the University of the Free State. The facility is utilised for undergraduate and postgraduate clinical simulation training, as well as interprofessional training and research. He has a special interest in simulation as training tool, precision skills training, and mastery of learning and simulation as tool to prepare students for interprofessional education and collaborative practice.

Prof Labuschagne is part of a multi-institutional consortium that developed the MySkills Medic app. It is a clinical procedural skills application aimed at graduating medical students, interns, and community-service doctors. He was appointed as a member of the Ophthalmology Foundation Education Simulation Subcommittee (affiliate of the International Council of Ophthalmology) tasked with developing a white paper to guide simulation training for ophthalmologists. He is involved in postgraduate supervision for master’s and PhD students in HPE.


News Archive

Researchers receive study grant for research into Congo Fever
2015-03-10

UFS researchers will be contributing significantly to the search for a vaccine against the deadly tick-borne disease known as Congo Fever.

Prof Felicity Burt from the Department of Medical Microbiology and Virology was recently awarded a research grant by the National Health Laboratory Service (NHLS) to study candidate vaccines for Crimean-Congo heamorrhagic fever (CCHF) virus and other arboviruses.

Arboviruses are viruses transmitted by mosquitoes, ticks, or other arthropods.

Prof Burt is an internationally-recognised expert on the Crimean-Congo haemorrhagic fever (CCHF). The Crimean-Congo haemorrhagic fever (CCHF) virus is a tick-borne virus that is associated with severe haemorrhagic disease in South Africa and other parts of Africa, Asia, and eastern Europe. Her interests focus on medically significant viruses that are transmitted by ticks and mosquitoes. Her research group is involved in determining the immune responses that are induced by different viral proteins.

Crimean-Congo haemorrhagic fever (CCHF) virus, a tick- borne virus found in Africa, Asia, the Balkans, and eastern Europe, causes severe viral haemorrhagic fever outbreaks.

Although a number of tick species are capable of becoming infected with CCHF virus, ticks of the genus Hyalomma, commonly referred to in SA as the “bont-legged ticks”, are the principal vector. The ticks have distinctive brown and white bands on their legs.

In February 1981, the first case of CCHF was recognised in South Africa (SA). To date, there have been nearly 200 cases of CCHF infection in SA with a 20% fatality rate. The majority of cases occurring in SA were in patients from the Northern Cape and Free State provinces.

“The funding that has been awarded will be used to profile immune responses against CCHF viral proteins, and investigate mechanisms and strategies to enhance these immune responses. We hope that the study will contribute knowledge towards the development of a vaccine against this medically significant virus.”

For more information or enquiries contact news@ufs.ac.za.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept